Ovarian cancer is one of the leading causes of cancer death among women due to difficulties in both diagnosis and therapy. Because of the insidious onset of the disease and the lack of reliable screening methods, two thirds of patients present with advanced stage disease upon diagnosis 1. The 5-yr relative survival rate is 27% for patients with advanced disease (stage III-IV) 2. Despite efforts aimed at early detection and new therapeutic approaches, the poor survival persists and may be explained by the heterogeneity and poorly understood pathogenesis of ovarian carcinoma (OC).
Platinum compounds comprise the most active chemotherapy available and constitute standard treatment after cytoreductive surgery for the majority of women diagnosed with ovarian cancer 3. First-line chemotherapy with platinum-based chemotherapy yields response rates of >80%. However, nearly all patients relapse and eventually develop platinum resistance 4. A biomarker capable of predicting platinum resistance at primary surgery could make it possible to identify patients who may not be suitable for platinum-based therapy, and thus be spared its side effects, or who could be eligible for other treatment options.
Claudins belong to a multigene family, with ∼24 members, and are considered one of the main tight junction (TJ) forming proteins 5,6. A TJ acts as a cellular barrier and is involved in paracellular permeability and cell polarity 7,8. Since the discovery of claudins in 1998, many studies have aimed to characterize the claudin family, revealing that the specific combination and coexpression of different claudin species determines the TJ barrier characteristics in a tissue-specific manner 9,10. TJ structure and function are often altered in human carcinomas, where TJ loss can contribute to cancer progression 11. For example, claudin-1 has been found to be downregulated in breast cancer, and claudin-2 is downregulated in breast and prostate cancer 12,13. In contrast, claudin-4 has been reported to be upregulated in pancreatic, colorectal, gastric, breast, prostate, and ovarian cancers 13–20. Previous studies have reported increased expression of claudins 3 and 4 in OC compared with normal ovarian surface epithelium and benign ovarian tumors 20–22.
Claudin-4 has been proposed as a possible diagnostic and prognostic biomarker in OC 3,23. However, there are limited and contradictory data regarding the involvement of claudins in chemotherapy resistance 24–26. Therefore, in this study we investigated the role of claudin-4 as a potential prognostic marker in 140 patients with primary OC. The relationship between platinum resistance and claudin-4 expression was also investigated.
MATERIALS AND METHODS
A total of 128 patients with OC were recruited consecutively in the southern Swedish health care region between 1998 and 2000 27. In addition, 18 patients with OC were recruited at the oncogenetic counseling at Lund University Hospital (Sweden) between 1981 and 1997. Six patients with unknown primary tumor or missing follow-up information were excluded. Thus, a cohort of 140 OC patients was assessed for claudin-4 protein expression.
The study was approved by the Ethics Committee at Lund University, Sweden, waiving the requirement for informed consent. The histologic subtype and grade were determined according to WHO 2014 28, and all tumors were staged according to the International Federation of Gynecology and Obstetrics (FIGO) criteria 29. Tumors were also classified into types I and II on the basis of both histology and grade 30. Platinum resistance was defined as primary progressive disease or recurrence within 6 mo of completing platinum-based therapy, the definition used in clinical practice today.
The majority of the tumors (70%) were of serous histology, followed by endometrioid, mucinous, and clear cell histologies. Approximately 75% of the patients were diagnosed with advanced stage (III/IV) disease, 64% were classified as type II, and 31/140 (22%) were carriers of a germline BRCA1 or BRCA2 mutation. Platinum-based chemotherapy was administered postoperatively to 132 patients: Carboplatin (AUC5) combined with paclitaxel (175 mg/m2) to 70 patients, Carboplatin (AUC5) combined with cyclophosphamide (500 mg/m2) to 25 patients, and unspecified platinum-based chemotherapy to 36 patients. Thirty-nine of the 132 patients who received chemotherapy (30%) were platinum resistant. Seven patients with early-stage (IA-B) disease and type I tumors were excluded from the study of claudin-4 expression as a treatment predictive marker for platinum response, as they had not received platinum-based therapy, in accordance with current guidelines. One patient was excluded from the same analysis because she received non–platinum-based chemotherapy postoperatively.
Data from a cohort of 1582 OC patients available through the online tool Kaplan-Meier Plotter 31 were used for validation.
Tissue Microarray (TMA) Construction and Immunohistochemistry
We used a TMA with 0.6 mm triplicate core needle biopsies from viable tumor areas 27. Sections, 3–4 μm in thickness, were deparaffinized, rehydrated, and stained. Antigen retrieval was performed using Dako Target retrieval solution of pH 6 (Dako A/S, Glostrup, Denmark) in a pressure cooker 2100 Retriever (Histolab Products AB, Gothenburg, Sweden). The sections were incubated with a claudin-4 mouse monoclonal antibody (Cat.No. 32-9400; Invitrogen Corporation, Camarillo) at a 1:100 dilution for 30 min. Immunohistochemical reactions were performed using the Autostainer Plus with the Dako REAL EnVision Detection system (Dako). Normal colon tissue was included as a positive control. The negative controls were ovarian stroma and follicle cells as well as smooth muscle and adipose tissue, all reported as negative for claudin-4 expression in The Human Protein Atlas 32. We also stained whole-tissue sections with benign ovary, fallopian tube, and endometrium, as well as 3 cases of serous cystadenomas.
A semiquantitative analysis of claudin-4 was performed by 2 blinded investigators following recommendations from a senior gynecologic pathologist (A.M.) and on the basis of the similar type of expression pattern observed for HER2. Claudin-4 staining was distinct and predominantly confined to the cell membrane. Two staining patterns were observed: (i) punctate and partial staining around the membrane; and (ii) complete membrane staining, covering the circumference of the membrane surface. Results from the core with the highest/strongest positivity were recorded into 5 subgroups on the basis of staining pattern and fraction of stained cancer cells (0: no staining, 1: <50% of cells with punctate/partial membrane staining, 2: 50%–75% of cells with punctate/partial membrane staining, 3: 50%–75% of cells with complete membrane staining, 4: >75% of cells with complete membrane staining).
As claudin-4 was expressed in the majority of OCs examined and no consensus for cutoff was available in the literature, an exploratory cutoff was used in the present study. Tumors with a ≥3+ score were considered to have high expression and the rest had low expression. This cutoff was established on the basis of the percentage of patients with primary platinum-resistant disease and the 2 staining patterns observed, before evaluating the effect on prognosis or platinum resistance.
The prognostic value of claudin-4 was investigated using 5-yr progression-free survival (PFS) time and 5-yr overall survival (OS) time as endpoints. PFS time was defined as the time interval between date of diagnosis and the first sign of disease recurrence (clinical and/or radiologic) or death, whichever occurred first. OS time was defined as the time interval between date of diagnosis and death. Of the patients who died within 5 yr after diagnosis, all but 2 died of ovarian cancer.
Statistical analyses were performed with SPSS for Windows version 22. To analyze the probability of a patient being platinum resistant, we calculated the relative risk (risk ratio) of high versus low claudin-4 expression with 95% confidence interval (95% CI). Associations between claudin-4 expression and platinum resistance and other clinical parameters were assessed using the Pearson χ2 test or the Fisher exact test, except for the ordinal variable stage, which was compared using the Mann-Whitney U test. Survival analyses for PFS and OS were performed using the Kaplan-Meier method, and differences between groups were tested using the logrank test. The effect of claudin-4 expression on survival was expressed using hazard ratios (HR) with 95% CI, estimated using univariable (crude effect) and multivariable (adjusting for clinical factors known to influence ovarian cancer survival) Cox regression. These factors included age at diagnosis (≥70 y vs. <70), tumor type (II vs. I), stage (III/IV vs. I/II), and BRCA1/2 mutation status (wild-type vs. mutation) 30,33–35 and were analyzed as binary factors. The cutoff of 70 yr was chosen on the basis of previous studies reporting an inferior outcome among elderly women 33. The classification into type I and II is made on the basis of both histology and grade, and defines 2 fundamentally different groups regarding tumorigenesis and prognosis 30. A large meta-analysis showed better OS and PFS for BRCA1 and BRCA2 mutation carriers compared with noncarriers 35. The prognostic factor residual disease following cytoreductive surgery was not included in the analyses, as this information was not documented. Cox regression was performed for the type II tumors alone as a stability analysis. All P-values are 2-sided.
Immunohistochemical Staining of Claudin-4
Seven of the 140 OCs displayed no staining, and the distribution in subgroups 1–4 was as follows: 1: n=32, 2: n=30, 3: n=18, 4: n=53. Thus, 71 cases (51%) displayed high claudin-4 expression. Figure 1 shows representative examples of high and low claudin-4 expression in OC. The expression of claudin-4 (low vs. high) in the different histologic subtypes, stages, and types, as well as in relation to age, BRCA1/2 mutation status, and platinum sensitivity, is shown in Table 1. High expression of claudin-4 correlated with high-grade serous histology compared with low-grade serous histology (χ2 test, P=0.037) and high age at diagnosis (χ2 test, P=0.049). A correlation between type II tumors and high claudin-4 expression was also observed, but this did not reach statistical significance (χ2 test, P=0.071). No correlation was found with BRCA1/2 status (wild-type vs. mutant, χ2 test, P=0.6) or stage (Mann-Whitney U test, P=0.1) (Table 1).
Two whole-tissue sections from a benign ovary with mesothelial hyperplasia revealed negative staining in the mesothelium, including the hyperplastic areas, whereas cortical serous inclusion cysts were strongly positive (Fig. 1). Epithelial cells in the 3 cases of serous cystadenomas also displayed strong claudin-4 expression. Other cell types in the ovary, including stromal and smooth muscle cells, showed no claudin-4 expression in all evaluated cases, in line with the Human Protein Atlas 32. Epithelium from normal fallopian tube and normal endometrium displayed high claudin-4 expression, also in line with the Human Protein Atlas (5 and 10 cases, respectively) 32.
Claudin-4 Expression and Platinum Sensitivity
Among the 132 patients who had received platinum-based chemotherapy, a patient with high claudin-4 expression had a 1.2 (95% CI=0.7–2.0, P=0.3) times higher risk (risk ratio) of being platinum resistant compared with a patient with low claudin-4 expression (Table 1). No associations with platinum responsiveness were found in separate analyses of type II tumors (n=86, P=0.6), type I tumors (n=42, Fisher Exact test, P=0.4), the serous subtype (n=97, P=0.7), late-stage (III-IV) disease (n=96, P=0.8), early-stage (I-II) disease (n=36, Fisher Exact test, P=0.2), or BRCA1/2 wild-type status (n=100, P=0.2).
Claudin-4 Expression and Prognosis of OC
Univariable analyses revealed an association between PFS and claudin-4 expression [HR=1.7 (1.1–2.6), P=0.020] (Table 2), with patients whose tumors expressed high levels of claudin-4 displaying an inferior outcome (Kaplan-Meier survival analysis, Fig. 2). Hazard of relapse was similar [HR=1.5 (1.0–2.4)] after adjustment for age, stage, type, and BRCA1/2 status in a multivariable analysis, but the evidence was slightly weaker (P=0.076) (Table 2). A comparable association was observed for OS in the univariable and multivariable analyses [HR=1.6 (1.0–2.4), P=0.041 and HR=1.5 (0.9–2.3), P=0.1] (Table 3). Analyses of type II tumors (n=86) showed a similar HR in multivariable analysis compared with all OCs [1.6 (0.9–2.8), P=0.078 for PFS and 1.6 (0.9–2.7), P=0.086 for OS].
To extend our findings, we investigated the role of CLDN4 mRNA levels in a cohort of 1582 OC patients available through the online tool Kaplan-Meier Plotter 31. The online tool comprises gene expression data and survival information from 13 independent public OC data sets (Gene Expression Omnibus and The Cancer Genome Atlas, n=28-565, 2015 version). The best performing threshold was used as cutoff, where 1105 patients (70%) were classified as CLDN4 low and 477 (30%) as CLDN4 high. These results were in line with our findings, as CLDN4-high patients displayed worse 5-yr OS in a univariable analysis [HR=1.3 (1.1–1.5), P<0.001] compared with CLDN4-low patients. Interestingly, the results were consistent after 10 yr of follow-up [see Fig. Supplemental Digital Content 1, http://links.lww.com/IJGP/A57, HR=1.3 (1. 2–1.5), P<0.001 for 10-yr OS]. However, a similar difference in 10-yr PFS was not observed [HR=1.2 (1.0–1.3), P=0.064].
A previous study has reported low or absent claudin-4 expression in normal ovarian surface epithelium and ovarian cystadenomas, in contrast to the high expression reported in OC, which according to the authors supports the involvement of claudin-4 in malignant transformation 20. We also found absence of expression in ovarian surface mesothelium, and interestingly also in the hyperplastic changes. In contrast to the former study, we found strong positive expression in cortical inclusion cysts (CIC) and serous cystadenomas. Furthermore, we also found strong positive expression in normal fallopian tube epithelium, consistent with data reported in the Human Protein Atlas 32.
A new paradigm for the pathogenesis of ovarian serous carcinoma, which questions the traditional model of ovarian mesothelium as the cell of origin for serous neoplasia, has been proposed. Cogent arguments support the role of fallopian tube epithelium in the genesis of both low and high-grade serous OCs 36–43. Serous tubal intraepithelial carcinomas found in prophylactic salpingo-oophorectomies in BRCA mutation carriers and sporadic cases of pelvic high-grade serous carcinoma are this far the best evidence of this extraovarian hypothesis 40,42,43. Furthermore, a new model of serous tumorigenesis proposes that normal tubal epithelium may shed and implant on the ovarian surface, thereby forming CICs. CICs and serous cystadenomas follow a benign course in most cases, but in some cases they can eventually lead to low and sometimes high-grade serous tumors 42. Thus, no conclusion regarding the involvement of claudin-4 in malignant transformation should be made on the basis of the comparison with ovarian mesothelium 40.
In our study, fallopian tube epithelium, as well as CICs and serous cystadenomas, displayed high claudin-4 expression, arguing against the upregulation of claudin-4 in malignant transformation. Furthermore, we examined endometrial epithelium, as endometrioid and clear cell tumors have been associated with endometriosis and because their gene expression profiles resemble those of endometrial epithelium 40,43. High endometrial claudin-4 expression was observed, also consistent with the Human Protein Atlas 32.
Decreased expression of claudins in cancer is in agreement with the hypothesis that tumorigenesis is accompanied by TJ disruption and loss of cell-cell adhesion, leading to disease dissemination 11. In contrast, overexpression of claudin-4 has been reported in several cancer types, including OC 20–22,44. Upregulation of CLDN3 and CLDN4 has been shown to increase cell invasion and motility in OC cell lines, and, conversely, knockdown caused the opposite effects, suggesting that claudin-3 and 4 may indeed promote ovarian tumorigenesis 45. In the present study, we found that high levels of claudin-4 were associated with decreased PFS and OS. The hazards of relapse or death were similar but not significant when adjusting for known prognostic factors, probably due to lack of power. The group with low claudin-4 expression had better prognosis and moreover displayed lower claudin-4 expression than the normal tissue levels used for comparison. Thus, there is a possibility that tumors that downregulate claudin-4 expression during malignant transformation become less aggressive tumors with better prognosis. Our findings also suggest that claudin-4 may have prognostic value.
Currently, the development of resistance can only be determined retrospectively, after patients have experienced the burden and toxicity of ineffective therapy 3. Clinical recurrences that occur within 6 mo after cessation of primary platinum-based chemotherapy are considered platinum resistant. This definition of platinum resistance is a strong predictor of response to second-line therapy, with very low response rates for patients defined as platinum resistant 46,47. A biomarker capable of predicting platinum resistance at primary surgery could enable the identification of patients not suitable for platinum-based therapy and who may thus be spared its side effects. Furthermore, patients with overexpression of claudin-4 and platinum-resistant disease may be candidates for clinical trials, including claudin-4-targeted therapy, as claudin-4 is potentially druggable using the C-terminal fragment of Clostridium perfringens enterotoxin 24–26. Such a biomarker could therefore provide the basis for individualization of therapy and improved outcome. In the current study we attempted to establish whether claudin-4 might be predictive of platinum sensitivity. Only a few reports are available on the association between platinum resistance and claudin-4 expression, and the results are contradictory. A proteomic study found 7-fold increased levels of claudin-4 protein in a platinum-resistant cell line compared with the sensitive parental line 3. Two studies have reported associations between high levels of claudin-4 protein and platinum resistance 24,26, whereas a third study failed to detect any association with platinum resistance or survival 25. These studies are, however, small (n=12–43) and may not be representative of the whole spectrum of OC. In fact, one of the studies reporting significantly higher claudin-4 expression in chemoresistant compared with chemosensitive cases had an overrepresentation of clear cell histology, known to be inherently more chemoresistant (10/43 cases, 23%), compared with our cohort (4/130 cases, 3%) 26. The association between platinum resistance and claudin-4 may hence be confounded by the histologic type, emphasizing the importance of stratification of histologic and probably also molecular subtypes when investigating potential treatment predictive biomarkers in OC. The other study compared CLDN4 mRNA levels at primary surgery from 6 patients with chemotherapy naive serous OC with chemotherapy resistant tumors from 6 patients with recurrent disease, showing CLDN4 upregulation at recurrence 24. In contrast, we investigated only tumor tissue from primary surgery, as we were interested in investigating the potential predictive value at first-line chemotherapy. However, pairwise comparisons between primary surgery and relapse may be interesting and could potentially inform treatment decisions in recurrent disease, as there may be a group of patients in whose tumors claudin-4 is upregulated upon development of platinum resistance. This line of research warrants further attention in larger cohorts with matched primary tumors and relapses. Nevertheless, we did not find a confident association between claudin-4 expression and platinum sensitivity. Our findings are, however, consistent with a previous report showing that claudin-4 expression, determined by qRT-PCR and IHC, did not differ between platinum-sensitive and platinum-resistant tumors in a cohort of 36 patients with high-grade, advanced-stage serous ovarian cancer 25. Furthermore, the definition of platinum resistance differed in the previously reported studies. Taken together, we did not find claudin-4 to be a useful predictive marker for platinum sensitivity in the clinical situation, either in an unselected cohort or within any other subgroup.
Of interest, claudin-4 has been suggested as a potential therapeutic target. Suppression of claudin-4 expression in human serous ovarian cancer cell lines by siRNA led to cellular accumulation of cisplatin and a significant increase in cisplatin sensitivity 26, suggesting that upregulation of claudin-4 expression may contribute to platinum resistance by decreasing drug uptake. Additional mechanisms of drug resistance may nevertheless also be present 48, and it remains to be confirmed whether claudin-4 overexpression is involved. We hypothesize that the heterogeneity and complexity of resistance mechanisms may explain why no differences between resistant and sensitive tumors were observed in the present study.
In conclusion, we identified claudin-4 as a potential prognostic biomarker in OC. Although previous studies have suggested a relationship between claudin-4 and platinum resistance, we were not able to validate this in our larger cohort. The druggable nature of claudin-4 nevertheless makes it appealing to pursue further as a target for circumventing platinum resistance. Further investigations aimed at studying the relationship between claudin-4 and platinum resistance are needed, in addition to validation studies to find application into clinical practice.
The authors would like to acknowledge Kristina Lövgren for assistance with TMAs and stainings.
1. Eisenhauer EL, Salani R, Copeland LJDi Saia PJ, Creasman WT. Epithelial ovarian cancer. Clinical Gynecologic Oncology, Eighth edn. Philadelphia, PA: Anne Altepeter; 2012:285–328.
2. NNA Howlader, Krapcho M, Garshell J. SEER Cancer Statistics Review, 1975-2011. Bethesda, MD: National Cancer Institute; 2013.
3. Stewart JJ, White JT, Yan X, et al. Proteins associated with cisplatin resistance in ovarian cancer cells identified by quantitative proteomic technology and integrated with mRNA expression levels. Mol Cell Proteomics 2006;5:433–43.
4. Sood AK, Buller RE. Drug resistance in ovarian cancer: from the laboratory to the clinic. Obstet Gynecol 1998;92:312–9.
5. Morita K, Furuse M, Fujimoto K, et al. Claudin multigene family encoding four-transmembrane domain protein components of tight junction strands. Proc Natl Acad Sci U S A 1999;96:511–6.
6. Gonzalez-Mariscal L, Betanzos A, Nava P, et al. Tight junction proteins. Prog Biophys Mol Biol 2003;81:1–44.
7. Cereijido M, Valdes J, Shoshani L, et al. Role of tight junctions in establishing and maintaining cell polarity. Annu Rev Physiol 1998;60:161–77.
8. Schneeberger EE, Lynch RD. The tight junction: a multifunctional complex. Am J Physiol Cell Physiol 2004;286:C1213–28.
9. Furuse M, Fujita K, Hiiragi T, et al. Claudin-1 and -2: novel integral membrane proteins localizing at tight junctions with no sequence similarity to occludin. J Cell Biol 1998;141:1539–50.
10. Tsukita S, Furuse M, Itoh M. Multifunctional strands in tight junctions. Nat Rev Mol Cell Biol 2001;2:285–93.
11. Oliveira SS, Morgado-Diaz JA. Claudins: multifunctional players in epithelial tight junctions and their role in cancer. Cell Mol Life Sci 2007;64:17–28.
12. Tokes AM, Kulka J, Paku S, et al. Claudin-1, -3 and -4 proteins and mRNA expression in benign and malignant breast lesions: a research study. Breast Cancer Res 2005;7:R296–305.
13. Soini Y. Expression of claudins 1, 2, 3, 4, 5 and 7 in various types of tumours. Histopathology 2005;46:551–60.
14. Nichols LS, Ashfaq R, Iacobuzio-Donahue CA. Claudin 4 protein expression in primary and metastatic pancreatic cancer: support for use as a therapeutic target. Am J Clin Pathol 2004;121:226–30.
15. Michl P, Buchholz M, Rolke M, et al. Claudin-4
: a new target for pancreatic cancer treatment using Clostridium perfringens
enterotoxin. Gastroenterology 2001;121:678–84.
16. de Oliveira SS, de Oliveira IM, De Souza W, et al. Claudins upregulation in human colorectal cancer. FEBS Lett 2005;579:6179–85.
17. Resnick MB, Gavilanez M, Newton E, et al. Claudin expression in gastric adenocarcinomas: a tissue microarray study with prognostic correlation. Hum Pathol 2005;36:886–92.
18. Cunningham SC, Kamangar F, Kim MP, et al. Claudin-4
, mitogen-activated protein kinase kinase 4, and stratifin are markers of gastric adenocarcinoma precursor lesions. Cancer Epidemiol Biomarkers Prev 2006;15:281–7.
19. Kominsky SL, Vali M, Korz D, et al. Clostridium perfringens enterotoxin elicits rapid and specific cytolysis of breast carcinoma cells mediated through tight junction proteins claudin 3 and 4. Am J Pathol 2004;164:1627–33.
20. Rangel LB, Agarwal R, D’Souza T, et al. Tight junction proteins claudin-3 and claudin-4
are frequently overexpressed in ovarian cancer but not in ovarian cystadenomas. Clin Cancer Res 2003;9:2567–75.
21. Hough CD, Sherman-Baust CA, Pizer ES, et al. Large-scale serial analysis of gene expression reveals genes differentially expressed in ovarian cancer. Cancer Res 2000;60:6281–7.
22. Santin AD, Zhan F, Bellone S, et al. Gene expression profiles in primary ovarian serous papillary tumors and normal ovarian epithelium: identification of candidate molecular markers for ovarian cancer diagnosis and therapy. Int J Cancer 2004;112:14–25.
23. Szabo I, Kiss A, Schaff Z, et al. Claudins as diagnostic and prognostic markers in gynecological cancer. Histol Histopathol 2009;24:1607–15.
24. Santin AD, Cane S, Bellone S, et al. Treatment of chemotherapy-resistant human ovarian cancer xenografts in C.B-17/SCID mice by intraperitoneal administration of Clostridium perfringens
enterotoxin. Cancer Res 2005;65:4334–42.
25. Litkouhi B, Kwong J, Lo CM, et al. Claudin-4
overexpression in epithelial ovarian cancer is associated with hypomethylation and is a potential target for modulation of tight junction barrier function using a C-terminal fragment of Clostridium perfringens
enterotoxin. Neoplasia 2007;9:304–14.
26. Yoshida H, Sumi T, Zhi X, et al. Claudin-4
: a potential therapeutic target in chemotherapy-resistant ovarian cancer. Anticancer Res 2011;31:1271–7.
27. Malander S, Rambech E, Kristoffersson U, et al. The contribution of the hereditary nonpolyposis colorectal cancer syndrome to the development of ovarian cancer. Gynecol Oncol 2006;101:238–43.
28. Kurman RJ, Carcangiu ML, Herrington CS, Young RH. eds. World Health Organization Classification of Tumours of the Female Reproductive Organs 4th ed. IARC: Lyon; 2014.
29. Heintz AP, Odicino F, Maisonneuve P, et al. Carcinoma of the ovary. FIGO 26th Annual Report on the Results of Treatment in Gynecological Cancer. Int J Gynaecol Obstet 2006;95(suppl 1):S161–92.
30. Shih IeM, Kurman RJ. Ovarian tumorigenesis: a proposed model based on morphological and molecular genetic analysis. Am J Pathol 2004;164:1511–8.
31. Gyorffy B, Lanczky A, Szallasi Z. Implementing an online tool for genome-wide validation of survival-associated biomarkers in ovarian-cancer using microarray data from 1287 patients. Endocr Relat Cancer 2012;19:197–208.
32. Uhlen M, Fagerberg L, Hallstrom BM, et al. Proteomics. Tissue-based map of the human proteome. Science 2015;347:1260419.
33. Sabatier R, Calderon B Jr, Lambaudie E, et al. Prognostic factors for ovarian epithelial cancer in the elderly: a case-control study. Int J Gynecol Cancer 2015;25:815–22.
34. Swenerton KD, Hislop TG, Spinelli J, et al. Ovarian carcinoma
: a multivariate analysis of prognostic factors. Obstet Gynecol 1985;65:264–70.
35. Zhong Q, Peng HL, Zhao X, et al. Effects of BRCA1- and BRCA2-related mutations on ovarian and breast cancer survival: a meta-analysis. Clin Cancer Res 2015;21:211–20.
36. Medeiros F, Muto MG, Lee Y, et al. The tubal fimbria is a preferred site for early adenocarcinoma in women with familial ovarian cancer syndrome. Am J Surg Pathol 2006;30:230–6.
37. Kindelberger DW, Lee Y, Miron A, et al. Intraepithelial carcinoma of the fimbria and pelvic serous carcinoma: evidence for a causal relationship. Am J Surg Pathol 2007;31:161–9.
38. Jarboe E, Folkins A, Nucci MR, et al. Serous carcinogenesis in the fallopian tube: a descriptive classification. Int J Gynecol Pathol 2008;27:1–9.
39. Gilks CB, Prat J. Ovarian carcinoma
pathology and genetics: recent advances. Hum Pathol 2009;40:1213–23.
40. Kurman RJ, Shih IeM. The origin and pathogenesis of epithelial ovarian cancer: a proposed unifying theory. Am J Surg Pathol 2010;34:433–43.
41. Jones PM, Drapkin R. Modeling high-grade serous carcinoma: how converging insights into pathogenesis and genetics are driving better experimental platforms. Front Oncol 2013;3:217.
42. Nik NN, Vang R, Shih IeM, et al. Origin and pathogenesis of pelvic (ovarian, tubal, and primary peritoneal) serous carcinoma. Annu Rev Pathol 2014;9:27–45.
43. Dubeau L. The cell of origin of ovarian epithelial tumours. Lancet Oncol 2008;9:1191–7.
44. Hibbs K, Skubitz KM, Pambuccian SE, et al. Differential gene expression in ovarian carcinoma
: identification of potential biomarkers. Am J Pathol 2004;165:397–414.
45. Agarwal R, D’Souza T, Morin PJ. Claudin-3 and claudin-4
expression in ovarian epithelial cells enhances invasion and is associated with increased matrix metalloproteinase-2 activity. Cancer Res 2005;65:7378–85.
46. Blackledge G, Lawton F, Redman C, et al. Response of patients in phase II studies of chemotherapy in ovarian cancer: implications for patient treatment and the design of phase II trials. Br J Cancer 1989;59:650–3.
47. Markman M, Markman J, Webster K, et al. Duration of response to second-line, platinum-based chemotherapy for ovarian cancer: implications for patient management and clinical trial design. J Clin Oncol 2004;22:3120–5.
48. Vasey PA. Resistance to chemotherapy in advanced ovarian cancer: mechanisms and current strategies. Br J Cancer 2003;89(suppl 3):S23–28.
Claudin-4; Ovarian carcinoma; Platinum resistance; Prognostic factor
Supplemental Digital Content
©2018International Society of Gynecological Pathologists